NCT00592319 · ADVERSE EVENTS

Adverse events

Celebrex (Celecoxib) Treatment of Laryngeal Papilloma · Source last updated 2012-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Primary: cardiovascular events for 12 months
Other-event reporting threshold: 0%

Others: laser and surgery complications for 12 months

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Experiment treated with both of PDL and Celecoxib	0 / 8	0 / 8	Not reported / Not reported
Control treatd with CO2 laser or microsurgery	0 / 2	0 / 2	Not reported / Not reported

Group identifiers: EG000: Experiment · EG001: Control

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

Others: laser and surgery complications for 12 months

event Groups

description
treated with both of PDL and Celecoxib
id
EG000
other Num Affected
0
other Num At Risk
8
serious Num Affected
0
serious Num At Risk
8
title
Experiment
description
treatd with CO2 laser or microsurgery
id
EG001
other Num Affected
0
other Num At Risk
2
serious Num Affected
0
serious Num At Risk
2
title
Control

frequency Threshold

time Frame

Primary: cardiovascular events for 12 months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice